Harrow, Inc. HROW
28.74 USD -0.63 (-2.15%)
Nov 12, 2026, 11:58 AM EST
28.67 Day range 29.54
25.76 52-week range 54.85
- YTD
- -41.35%
- 1 year
- -25.23%
News
globenewswire.com Harrow to Participate in Two Investor Conferences in November NASHVILLE, Tenn., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will…
seekingalpha.com Harrow, Inc. (HROW) Q3 2026 Earnings Call Transcript Harrow, Inc. ( HROW ) Q3 2026 Earnings Call November 10, 2026 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO, Chairman of the…
marketbeat.com Harrow Q3 Earnings Call Highlights Harrow NASDAQ: HROW reported record third-quarter revenue and reaffirmed its full-year sales forecast, but sharply reduced its adjusted earnings outlook as lower-than-expected margins and accelerated…
benzinga.com AAON, Ziprecruiter, Rackspace Technology, Babcock & Wilcox And Other Big Stocks Moving Higher On Tuesday U.S. stocks fell, but AAON surged 23% on strong earnings and raised guidance. ZipRecruiter, Securitize and Senseonics led other gainers.
benzinga.com Harrow Q3 2026 Earnings Call Transcript Harrow (NASDAQ:HROW) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings…
zacks.com Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Harrow (HROW) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
zacks.com Harrow (HROW) Q3 Earnings Lag Estimates Harrow (HROW) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.33 per share a year ago.
benzinga.com Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $349.747M Est Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000 million-$365.000 million vs $349.747 million estimate.
benzinga.com Harrow Q3 EPS $0.25 Beats $0.22 Estimate, Sales $99.297M Beat $98.501M Estimate Harrow (NASDAQ:HROW) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.22 by 13.64 percent. This is a 24.24 percent decrease over earnings of $0.33 per…
globenewswire.com Harrow Announces Third Quarter 2026 Financial Results Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year Branded revenue of $83.5 million, up 62% year over year and…
benzinga.com Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
benzinga.com Leerink Partners Initiates Coverage On Harrow with Outperform Rating, Announces Price Target of $45 Leerink Partners analyst Daniel Clark initiates coverage on Harrow (NASDAQ:HROW) with a Outperform rating and announces Price Target of $45.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half Harrow (NASDAQ: HROW) posts positive study results for IHEEZO ophthalmic gel, significantly reducing IVT injection patient discomfort.
benzinga.com Harrow Reports Statistically Significant Results Favoring IHEEZO In Intravitreal Injection Study Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study…
benzinga.com OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures mostly lower. OppFi (OPFI) shares fall after missing Q2 earnings and cutting FY26 guidance. Other stocks also down in pre-market.- benzinga.com Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $348.468M Est Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000 million-$365.000 million vs $348.468 million estimate.
benzinga.com Harrow Q2 EPS $(0.46) Misses $(0.21) Estimate, Sales $70.661M Beat $70.342M Estimate Harrow (NASDAQ:HROW) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.21) by 119.05 percent. This is a 453.85 percent decrease over earnings of $0.13…
benzinga.com Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter earnings and revenue beat estimates.- benzinga.com Samsung Bioepis, Harrow Present SB11 Safety Data At ASRS 2026 Annual Meeting; Interim PMS Study Shows SB11 Comparable To Lucentis A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumabIn treatment-naïve patients, SB11 provided functional…
- benzinga.com Harrow Presents Three Studies Supporting IHEEZO, Low Viscosity Ocular Anesthetic Gel, And BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTIS At ASRS 2026 Annual Meeting Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO® (chloroprocaine HCl…
benzinga.com 8 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Harrow Announces Commercial Launch Of BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTISi And Developed By Samsung Bioepis Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar…
benzinga.com Harrow Adds Another Piece To Ophthalmology Strategy Harrow relaunches Verkazia for VKC treatment, targeting pediatric eye disease with a steroid-sparing therapy option.
benzinga.com Harrow Re-Launches Steroid-Sparing VERKAZIA For Vernal Keratoconjunctivitis, Targeting Underlying Inflammatory Mechanisms In Pediatric Patients VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access…
benzinga.com Alpha Buying: When CEOs and CFOs Buy Together - benzinga.com Cantor Fitzgerald Maintains Overweight on Harrow, Lowers Price Target to $88 Cantor Fitzgerald analyst Steve Seedhouse maintains Harrow (NASDAQ:HROW) with a Overweight and lowers the price target from $91 to $88.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Transcript: Harrow Q1 2026 Earnings Conference Call 
benzinga.com AST SpaceMobile Posts Downbeat Q1 Results, Joins Hims & Hers Health, Gitlab And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures lower, Nasdaq down 200 points. AST SpaceMobile shares dip 11% after reporting worse-than-expected financial results.
benzinga.com Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising guidance. Other gainers include Buzzfeed, MacroGenics, & SI-Bone.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $351.380M Est Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000 million-$365.000 million vs $351.380 million estimate.
- benzinga.com Harrow Q1 EPS $(0.74) Misses $(0.39) Estimate, Sales $44.203M Miss $52.420M Estimate Harrow (NASDAQ:HROW) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.39) by 89.74 percent. This is a 94.74 percent decrease over losses of $(0.38)…
benzinga.com Earnings Scheduled For May 11, 2026 
benzinga.com LogiCare3PL Selected As Distribution Partner For Harrow's Portfolio Of Ophthalmic Disease Management Solutions LogiCare3PL today announced it has been selected by Harrow, Inc. (NASDAQ:HROW) as a distribution partner for Harrow's portfolio of ophthalmic disease management solutions. Effective February 1, 2026,…- benzinga.com B. Riley Securities Reiterates Buy on Harrow, Lowers Price Target to $65 B. Riley Securities analyst Mayank Mamtani reiterates Harrow (NASDAQ:HROW) with a Buy and lowers the price target from $74 to $65.
- benzinga.com Harrow Announces Additional $50M Note Offering; 8.625% Senior Unsecured Notes Due 2030 The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that…
benzinga.com These Analysts Revise Their Forecasts On Harrow Following Q4 Results - benzinga.com Cantor Fitzgerald Maintains Overweight on Harrow, Lowers Price Target to $91 Cantor Fitzgerald analyst Steve Seedhouse maintains Harrow (NASDAQ:HROW) with a Overweight and lowers the price target from $94 to $91.
- benzinga.com HC Wainwright & Co. Maintains Buy on Harrow, Raises Price Target to $70 HC Wainwright & Co. analyst Yi Chen maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $69 to $70.
benzinga.com Why Is Eye-Disease-Focused Harrow Stock Falling Today? (UPDATED) Harrow stock drops after earnings miss and weak 2026 outlook, despite revenue growth and new product plans.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session MDB stock fell 27.2% in pre-market trading after reporting Q4 earnings of $1.65 per share, revenue of $695.07M, and Q1 guidance below estimates.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com The FDA Clears Harrow's Investigational New Drug Application To Support A Planned Phase 3 Trial Of Triesence (Preservative-free Triamcinolone Acetonide Injectable Suspension) 40 mg/ml For Ocular Inflammation And Pain Following Cataract Surgery The planned Phase 3 study is a randomized, placebo-controlled, double-masked, multicenter clinical trial designed to evaluate the safety and efficacy of TRIESENCE in patients undergoing cataract…
benzinga.com Why Ouster Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket Shares of Ouster Inc (NASDAQ:OUST) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quar
benzinga.com Harrow Earnings Review: Q4 Summary - benzinga.com Harrow Q4 EPS $0.17 Misses $0.38 Estimate, Sales $89.092M Beat $88.447M Estimate Harrow (NASDAQ:HROW) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.38 by 55.61 percent. This is a 57.5 percent decrease over earnings of $0.40 per…